FTI-277 | CAS# 170006-73-2 | Biochemical

MedKoo Cat#: 575706 | Name: FTI-277

Description:

WARNING: This product is for research use only, not for human or veterinary use.

FTI-277 is a ras CAAX (C - Cys; A - aliphatic amino acid; X - Ser or Met) peptidomimetic that inhibits farnesyltransferase and blocks Ras oncogenic signaling by accumulating Ras/Raf complexes in the cytoplasm.

Chemical Structure

FTI-277

CAS#170006-73-2 (free base)

Theoretical Analysis

MedKoo Cat#: 575706

Name: FTI-277

CAS#: 170006-73-2 (free base)

Chemical Formula: C22H29N3O3S2

Exact Mass: 447.1650

Molecular Weight: 447.61

Elemental Analysis: C, 59.03; H, 6.53; N, 9.39; O, 10.72; S, 14.32

Price and Availability

Size	Price	Availability	Quantity

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

170006-73-2 (free base) 180977-34-8 (HCl) 1217447-06-7 (TFA)

Synonym

FTI 277; FTI277; FTI-277

IUPAC/Chemical Name

L-Methionine, N-((5-((2-amino-3-mercaptopropyl)amino)(1,1'-biphenyl)-2-yl)carbonyl)-, methyl ester, (R)-

InChi Key

GKFPROVOIQKYTO-UZLBHIALSA-N

InChi Code

InChI=1S/C22H29N3O3S2/c1-28-22(27)20(10-11-30-2)25-21(26)18-9-8-17(24-13-16(23)14-29)12-19(18)15-6-4-3-5-7-15/h3-9,12,16,20,24,29H,10-11,13-14,23H2,1-2H3,(H,25,26)/t16-,20+/m1/s1

SMILES Code

COC(=O)[C@H](CCSC)NC(=O)c1ccc(NC[C@@H](N)CS)cc1c2ccccc2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

FTI-277 is an inhibitor of farnesyl transferase (FTase); a highly potent Ras CAAX peptidomimetic which antagonizes both H- and K-Ras oncogenic signaling.

In vitro activity:

MTT assay demonstrated that FTI-277 inhibited proliferation of the H-Ras-MCF10A, Hs578T and MDA-MB-231 cells in a dose-dependent manner (Fig. 2). FTI-277 exerted a strong anti-proliferative effect on the H-Ras-MCF10A and Hs578T cells with 50% inhibitory concentration (IC50) values of 6.84 and 14.87 µM for 48 h, respectively. FTI-277 treatment inhibited proliferation of the MDA-MB-231 cells with an IC50 value of 29.32 µM for 48 h. The results suggest that breast cells in which H-Ras is activated may be more susceptible to FTI-277 compared with the cells with wild-type H-Ras. Reference: Oncol Lett. 2016 Sep;12(3):2222-2226. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998514/

In vivo activity:

A single injection of farnesyltransferase inhibitor (25 mg/kg b.wt. FTI-277) at 2 h after CLP prolonged survival time of septic mice compared with vehicle alone. Kaplan-Meier survival curve analysis showed statistically significant beneficial effects of FTI-277 compared with vehicle alone (p < 0.0001) (Fig. 1A). χ2 test also revealed that FTI-277 significantly reduced mortality after CLP in mice (p = 0.001). Reference: J Pharmacol Exp Ther. 2011 Dec; 339(3): 832–841. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226365/

Preparing Stock Solutions

The following data is based on the product molecular weight 447.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Ponnusamy A, Sinha S, Hyde GD, Borland SJ, Taylor RF, Pond E, Eyre HJ, Inkson CA, Gilmore A, Ashton N, Kalra PA, Canfield AE. FTI-277 inhibits smooth muscle cell calcification by up-regulating PI3K/Akt signaling and inhibiting apoptosis. PLoS One. 2018 Apr 24;13(4):e0196232. doi: 10.1371/journal.pone.0196232. PMID: 29689070; PMCID: PMC5916518. 2. Lee KH, Koh M, Moon A. Farnesyl transferase inhibitor FTI-277 inhibits breast cell invasion and migration by blocking H-Ras activation. Oncol Lett. 2016 Sep;12(3):2222-2226. doi: 10.3892/ol.2016.4837. Epub 2016 Jul 11. PMID: 27602167; PMCID: PMC4998514. 3. Li W, Tu J, Liu X, Yang W. Farnesyltransferase inhibitor FTI-277 inhibits PD-L1 expression on septic spleen lymphocytes and promotes spleen lymphocyte activation. Clin Exp Immunol. 2017 Oct;190(1):8-18. doi: 10.1111/cei.12995. Epub 2017 Jul 14. PMID: 28556912; PMCID: PMC5588849. 4. Yang W, Yamada M, Tamura Y, Chang K, Mao J, Zou L, Feng Y, Kida K, Scherrer-Crosbie M, Chao W, Ichinose F, Yu YM, Fischman AJ, Tompkins RG, Yao S, Kaneki M. Farnesyltransferase inhibitor FTI-277 reduces mortality of septic mice along with improved bacterial clearance. J Pharmacol Exp Ther. 2011 Dec;339(3):832-41. doi: 10.1124/jpet.111.183558. Epub 2011 Aug 26. PMID: 21873557; PMCID: PMC3226365.

In vitro protocol:

In vivo protocol:

1. Li W, Tu J, Liu X, Yang W. Farnesyltransferase inhibitor FTI-277 inhibits PD-L1 expression on septic spleen lymphocytes and promotes spleen lymphocyte activation. Clin Exp Immunol. 2017 Oct;190(1):8-18. doi: 10.1111/cei.12995. Epub 2017 Jul 14. PMID: 28556912; PMCID: PMC5588849. 2. Yang W, Yamada M, Tamura Y, Chang K, Mao J, Zou L, Feng Y, Kida K, Scherrer-Crosbie M, Chao W, Ichinose F, Yu YM, Fischman AJ, Tompkins RG, Yao S, Kaneki M. Farnesyltransferase inhibitor FTI-277 reduces mortality of septic mice along with improved bacterial clearance. J Pharmacol Exp Ther. 2011 Dec;339(3):832-41. doi: 10.1124/jpet.111.183558. Epub 2011 Aug 26. PMID: 21873557; PMCID: PMC3226365.

1: Yang W, Yamada M, Tamura Y, Chang K, Mao J, Zou L, Feng Y, Kida K, Scherrer-Crosbie M, Chao W, Ichinose F, Yu YM, Fischman AJ, Tompkins RG, Yao S, Kaneki M. Farnesyltransferase inhibitor FTI-277 reduces mortality of septic mice along with improved bacterial clearance. J Pharmacol Exp Ther. 2011 Dec;339(3):832-41. doi: 10.1124/jpet.111.183558. Epub 2011 Aug 26. PubMed PMID: 21873557; PubMed Central PMCID: PMC3226365. 2: Kim DM, Ryu SW, Choi C. Long-term treatment of farnesyltransferase inhibitor FTI-277 induces neurotoxicity of hippocampal neurons from rat embryo in a ROS-dependent manner. Biochem Biophys Res Commun. 2010 Dec 3;403(1):91-6. doi: 10.1016/j.bbrc.2010.10.123. Epub 2010 Oct 30. PubMed PMID: 21040708. 3: Doisneau-Sixou SF, Cestac P, Faye JC, Favre G, Sutherland RL. Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression. Int J Cancer. 2003 Sep 20;106(5):789-98. PubMed PMID: 12866041. 4: Girgert R, Wittrock J, Pfister S, Schweizer P. Farnesyltransferase inhibitor FTI-277 prevents autocrine growth stimulation of neuroblastoma by BDNF. J Cancer Res Clin Oncol. 2003 Apr;129(4):227-33. Epub 2003 Apr 17. PubMed PMID: 12700894. 5: Ellis CA, Vos MD, Wickline M, Riley C, Vallecorsa T, Telford WG, Zujewskil J, Clark GJ. Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines. Breast Cancer Res Treat. 2003 Mar;78(1):59-67. PubMed PMID: 12611458.